In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
|Articles|January 30, 2021
How Mental Health Can Impact Vaccine Efficacy
Author(s)Killian Meara
A discussion surrounding how environmental and behavioral factors can lower immune system responses.
Advertisement
In a conversation talking about these issues, Annelise Madison, a PhD Candidate in Clinical Psychology at the Institute for Behavioral Medicine Research at The Ohio State University College of Medicine, discusses the immune systems response.
“What can happen with chronic stress, depression, loneliness, is that there are significant neuroendocrine changes that can happen, and these changes can happen systemically and impact both T-cell and antibody responses to vaccination,” Madison said.
Although this is having a severely negative impact on the population at large, there are many ways one can mitigate these issues.
“The good news is that there are things we can do. For instance, prioritizing sleep shortly before and after you get the vaccine can be so important for immune function. Same with exercise… these are ways in the short term we can boost our vaccine responses.”
Advertisement
Related to this article
FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
Following World Rabies Day and a CDC health advisory on a 17% rise in exposure-related calls, Rodney E. Rohde, PhD, explains what the increase means, what people should do when they have an animal bite or scratch, and how clinicians should assess risk and administer post-exposure prophylaxis (PEP).
The monoclonal antibody, Brelovitug, met the combined virologic and ALT response end point at week 24 in AZURE-1, with 56% response on 300 mg weekly and 45% on 900 mg every four weeks. The manufacturer projects a potential US launch in the fourth quarter of 2027.
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
Advertisement
Advertisement
Trending on Contagion Live
1
New IDSA/ESCMID S aureus Bacteremia Consensus Statements: a Risk Stratification Framework
2
Further Insights, Treatment Considerations Around the PETERPEN Study
3
On World Rabies Day, When to Seek Treatment, Clinical Considerations for Post Exposure Prophylaxis
4
VYD2311 Shows Superior Tolerability to mRNA COVID-19 Vaccine in Phase 3 Study
5